Reported resultsCompany-reported
What was reported
DURHAM, N.C., August 12, 2026 – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the second quarter ended June 30, 2026 and provided a business update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 12, 2026 · Open the source ↗
What the evidence supports
Humacyte published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineHumacyte Announces Second Quarter 2026 Financial Results and Provides Business UpdateU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 12, 2026 · Open the source ↗
Press release lead paragraphDURHAM, N.C., August 12, 2026 – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the second quarter ended June 30, 2026 and provided a business update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 12, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.